Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.83 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione SCHEMBL5131162 | 1.00 | PTGS1 (0.83) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL19612768 | 1.00 | PTGS1 (0.83) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL237151 | 1.00 | PTGS1 (0.83) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL28054046 | 0.94 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL5147539 | 0.94 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL28735728 | 0.93 | PTGS1 (0.76) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL1681676 | 0.93 | PTGS1 (0.80) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL1681679 | 0.93 | PTGS1 (0.80) | PTGS1GSTK1GLO1KDM4EMAPT | |
| Glutathione SCHEMBL8215201 | 0.93 | PTGS1 (0.92) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL8215210 | 0.93 | PTGS1 (0.92) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333447-A1 | HORMONE DELIVERY SYSTEM AND METHOD | BAUCOM KARAN Y (US) | 2017-11-23 | — | — | US | claimed |
| US-10561673-B2 | Dendrimer based nanodevices for therapeutic and imaging purposes | WAYNE STATE UNIVERSITY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190247407-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | Ashvattha Therapeutics, Inc. | 2019-08-15 | — | — | US | disclosed |
| US-10172951-B2 | Dendrimer based nanodevices for therapeutic and imaging purposes | WAYNE STATE UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20150141350-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | Ashvattha Therapeutics, Inc. | 2015-05-21 | — | — | US | disclosed |
| US-8889101-B2 | Dendrimer based nanodevices for therapeutic and imaging purposes | WAYNE STATE UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2442797-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | Wayne State University (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120003155-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | NATIONAL INSTITUTES OF HEALTH (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010147831-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | WAYNE STATE UNIVERSITY (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7504377-B2 | Nitric oxide-blocked cross-linked tetrameric hemoglobin | IKOR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080096805-A1 | deoxygenated, endotoxin-free and stroma-free transport proteins, incapable of binding with nitric oxide, useful as substitutes for erythrocytes in mammals and for treating disorders where oxygen delivery agents are of benefit | IKOR, INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008008380-A1 | COMBINATION THERAPY FOR ADDICTION DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-0966196-A4 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | VIRODENE PHARMACEUTICAL HOLDIN (ZA) | 2002-03-27 | — | — | EP | disclosed |
| EP-1011567-A1 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | Cryopreservation Technologies CC (ZA) | 2000-06-28 | — | — | EP | disclosed |
| EP-1011567-A4 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | CRYOPRESERVATION TECH CC (ZA) | 2000-06-28 | — | — | EP | disclosed |
| EP-0966196-A1 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Cryopreservation Technologies CC (ZA) | 1999-12-29 | — | — | EP | disclosed |
| US-5935597-A | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes | CRYOPRESERVATION TECHNOLOGIES CC (ZA) | 1999-08-10 | — | — | US | disclosed |
| WO-1998056325-A1 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | CRYOPRESERVATION TECHNOLOGIES CC (ZA) | 1998-12-17 | — | — | WO | disclosed |
| WO-1997022248-A9 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | — | 1997-10-02 | — | — | WO | disclosed |
| WO-1997022248-A1 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | CRYOPRESERVATION TECHNOLOGIES CC (ZA) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141350-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | PAM, MUC1, AADAC | PTGS1 1281/4885GSTK1 128/4885GLO1 377/4885 |
| US-20120003155-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | PAM, MUC1, AADAC | PTGS1 1281/4885GSTK1 128/4885GLO1 377/4885 |
| US-10172951-B2 | Dendrimer based nanodevices for therapeutic and imaging purposes | PAM, MUC1, AADAC | PTGS1 1281/4885GSTK1 128/4885GLO1 377/4885 |
| US-20190247407-A1 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES | PAM, MUC1, AADAC | PTGS1 1281/4885GSTK1 128/4885GLO1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.